Gil D. Rabinovici

Jan 8, 2025 | alz-journals.onlinelibrary.wiley.com | Gil D. Rabinovici |Biomedical Imaging |David S. Knopman |Javier Arbizu

1 INTRODUCTION AND SCOPE Alzheimer's disease (AD) is defined neuropathologically by the deposition of extracellular plaques composed of aggregated forms of the amyloid-beta (Aβ) polypeptide and intraneuronal neurofibrillary tangles (NFTs) composed of aggregated hyperphosphorylated tau protein.1, 2 In the past 20 years, positron emission tomography (PET) radiotracers have been developed to image amyloid plaques and tau tangles in vivo.3-9 Currently, three fluorine-18-labeled amyloid...

Jan 7, 2025 | jnm.snmjournals.org | Gil D. Rabinovici |David S. Knopman |Javier Arbizu |Tammie L.S. Benzinger

Using the evidence summary, their clinical experience and expertise, and their knowledge of research outside of the scope of the evidence review, the workgroup used a modified Delphi approach to reach consensus on ratings for each of the clinical scenarios. This approach consisted of an online survey and 2 rounds of virtual scoring. When rating each scenario, workgroup members were asked to assess the benefits and risks to patients of using amyloid and tau PET imaging for the diagnosis of AD.

Nov 21, 2024 | neurologylive.com | Gil D. Rabinovici |Isabella Ciccone

WATCH TIME: 7 minutes"The consensus of the committee ultimately was that the blood-based biomarkers are very close, and maybe in the near future, a positive blood-based biomarker would be sufficient to establish eligibility for treatment. But we're not quite there yet."Alzheimer disease (AD), a progressive neurodegenerative disorder, affects millions globally and remains a leading cause of dementia.

Nov 12, 2024 | neurologylive.com | Gil D. Rabinovici |Isabella Ciccone

WATCH TIME: 7 minutes"The Appropriate Use Recommendations for donanemab are designed with a conservative approach that emphasizes patient safety, addressing the real-world risks of amyloid-related imaging abnormalities and other potential adverse effects."Earlier this summer, the FDA approved donanemab (Kisulna; Eli Lilly), a monoclonal IgG1 antiamyloid antibody, for treating patients in the early clinical stages of Alzheimer disease (AD).

Jul 28, 2024 | jamanetwork.com | Gil D. Rabinovici |Biomedical Imaging

Blood-Based Biomarkers for Alzheimer Disease—Ready for Primary Care? Blood Biomarkers to Detect Alzheimer Disease in Primary and Secondary Care Sebastian Palmqvist, MD, PhD; Pontus Tideman, MSc; Niklas Mattsson-Carlgren, MD, PhD; Suzanne E. Schindler, MD, PhD; Ruben Smith, MD, PhD; Rik Ossenkoppele, PhD; Susanna Calling, MD, PhD; Tim West, PhD; Mark Monane, MD, MBA; Philip B. Verghese, PhD; Joel B.